The Medicines and Healthcare products Regulatory Agency (MHRA) has announced it is taking forward its new ‘regulatory sandbox’, the AI-Airlock, that will provide a regulator-monitored virtual area for developers to generate robust evidence for their advanced technologies.
Artificial Intelligence (AI) in healthcare represents the exciting potential to improve patient outcomes in many ways, for example through improving diagnoses and treatment selections, optimising medication dosages, and providing enhanced personalised care for patients. However, technologies like these can sometimes be challenging to test using traditional trial techniques and would therefore benefit from the AI-Airlock project’s collaborative approach to identifying and managing evidence requirements. This means patients could benefit from faster access to developing technologies such as improved diagnostics or precision medicine as a result of today’s announcement.
This new partnership between government, regulators and industry will see advanced AI technology used in NHS settings, with strict safety controls, ahead of navigating regulatory approval. Where successful the AI-Airlock will help NHS patients to benefit earlier from emerging technologies before they are available anywhere else in the world. This will support innovators to work within the current regulatory system, identify where their products need to build more evidence needed for a safety and efficacy assessment and help resolve these issues.
It follows a robust process, so manufacturers of software and AI medical devices understand and deliver what is required to ensure the real-world viability of these devices. The process, following the ‘regulatory sandbox’ model is a mechanism to assist in safe development and deployment of software and AI medical devices. This learning can then be shared, helping to provide an evidence base that promotes a wider understanding of the challenges and potential solutions that are available.
This initiative demonstrates the MHRA’s commitment to building on its existing capabilities and investing its regulatory expertise to enable highly innovative areas of medical product development, bringing cutting-edge products to UK patients faster, without compromising on its robust standards of safety and performance.
The AI-Airlock is designed to be a collaborative space, bringing together expertise from innovators, regulatory organisations including Approved Bodies, Government, the NHS and academia.
Government funding from the Department of Science, Innovation and Technology and the Department of Health and Social Care will enable development of the service, so that it will be ready to launch in April 2024.
Dr Paul Campbell, MHRA Head of Software and AI, said: “Building on the success of the regulatory sandbox, we are excited to deliver a new, world-leading methodology to support safe early access to AI for patients and healthcare. We need to ensure that AI is safe and properly regulated, but in a way that doesn’t stifle innovation and access to the latest of medical technologies to improve patient care. The new AI-Airlock scheme run by the MHRA will give us answers about how best to provide safe and effective products, such as AI-driven medical devices, to the NHS and patients.”
